Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Ageno, Walter
Membro del Collaboration Group
;
2020-01-01

Abstract

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
2020
COVID-19; SARS-CoV-2; anticoagulant; antiplatelet; antithrombotic therapy; thrombosis; Anticoagulants; Betacoronavirus; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Treatment Outcome; Coronavirus Infections; Pandemics; Pneumonia, Viral; Thromboembolism
Bikdeli, Behnood; Madhavan, Mahesh V; Jimenez, David; Chuich, Taylor; Dreyfus, Isaac; Driggin, Elissa; Nigoghossian, Caroline Der; Ageno, Walter; Madjid, Mohammad; Guo, Yutao; Tang, Liang V; Hu, Yu; Giri, Jay; Cushman, Mary; Quéré, Isabelle; Dimakakos, Evangelos P; Gibson, C Michael; Lippi, Giuseppe; Favaloro, Emmanuel J; Fareed, Jawed; Caprini, Joseph A; Tafur, Alfonso J; Burton, John R; Francese, Dominic P; Wang, Elizabeth Y; Falanga, Anna; Mclintock, Claire; Hunt, Beverley J; Spyropoulos, Alex C; Barnes, Geoffrey D; Eikelboom, John W; Weinberg, Ido; Schulman, Sam; Carrier, Marc; Piazza, Gregory; Beckman, Joshua A; Steg, P Gabriel; Stone, Gregg W; Rosenkranz, Stephan; Goldhaber, Samuel Z; Parikh, Sahil A; Monreal, Manuel; Krumholz, Harlan M; Konstantinides, Stavros V; Weitz, Jeffrey I; Lip, Gregory Y H
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2097746
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1405
  • Scopus 2185
  • ???jsp.display-item.citation.isi??? 1960
social impact